• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WU You, TANG Tingting, ZHU Qinhua, JIN Liang, PAN Yi. Mechanisms of miR-29a in migration and invasion of breast cancer MCF-7 cells in vitro[J]. Journal of China Pharmaceutical University, 2018, 49(3): 348-353. DOI: 10.11665/j.issn.1000-5048.20180314
Citation: WU You, TANG Tingting, ZHU Qinhua, JIN Liang, PAN Yi. Mechanisms of miR-29a in migration and invasion of breast cancer MCF-7 cells in vitro[J]. Journal of China Pharmaceutical University, 2018, 49(3): 348-353. DOI: 10.11665/j.issn.1000-5048.20180314
shu

Mechanisms of miR-29a in migration and invasion of breast cancer MCF-7 cells in vitro

More Information
    Graphical Abstract
    • Abstract
  • The aim of this study was to investigate the effect and mechanisms of miR-29a in migration and invasion of human breast cancer MCF-7 cells in vitro. MCF-7 cells were treated with miR-29a mimic or miR-29a inhibitor to up-regulate/down-regulate the expression level of miR-29a. Wound-healing assay and transwell chamber were employed to determine cell migration and invasion in vitro. The target gene of miR-29a was predicted with the Targetscan7. 1 database and verified through luciferase reporter method. The effects of miR-29a on the expression of the potential target were detected by Western blot and real-time PCR. Results showed that in vitro migration and invasion ability of MCF-7 cells was increased significantly by miR-29a, which could target HBP1 in the 3′-UTR region. The protein expression of HBP1 was decreased by miR-29a overexpression. However, the alteration of miR-29a had no significant effect on the expression of HBP1 mRNA. The results validated that miR-29a, highly expressed in breast cancer, could down-regulate HBP1, which in turn promotes migration and invasion ability of breast cancer cells, thus promoting breast cancer metastasis.
    • FullText(HTML)
    • References (20)
  • [1]
    Redig AJ,McAllister SS.Breast cancer as a systemic disease:a view of metastasis[J].J Intern Med,2013,274(2):113-126.
    [2]
    Zhang K,Zhang Y,Liu C,et al.MicroRNAs in the diagnosis and prognosis of breast cancer and their therapeutic potential[J].Int J Oncol,2014,45(3):950-958.
    [3]
    Di Leva G,Garofalo M,Croce CM.microRNAs in cancer[J].Annu Rev Pathol,2014,9:287-314.
    [4]
    Pei YF,Lei Y,Liu XQ.MiR-29a promotes cell proliferation and EMT in breast cancer by targeting ten eleven translocation 1[J].Biochim Biophys Acta,2016,1862(11):2177-2185.
    [5]
    Rostas JW,Pruitt HC,Metge BJ,et al.microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer[J].Mol Cancer,2014,13:200.
    [6]
    Shukla GC,Singh J,Barik S.MicroRNAs:processing,maturation,target recognition and regulatory functions[J].Mol Cell Pharmacol,2011,3(3):83-92.
    [7]
    Debacker K,Kooy RF.Fragile sites and human disease[J].Hum Mol Genet,2007,16(2):150-158.
    [8]
    Chen L,Xiao H,Wang ZH,et al.miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A[J].BMB Rep,2014,47(1):39-44.
    [9]
    Tréhoux S,Lahdaoui F,Delpu Y,et al.Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells[J].Biochim Biophys Acta,2015,1853(10 Pt A):2392-2403.
    [10]
    Yamamoto N,Kinoshita T,Nohata N,et al.Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma[J].Int J Oncol,2013,43(6):1855-1863.
    [11]
    Pasqualini L,Bu H,Puhr M,et al.miR-22 and miR-29a are members of the androgen receptor cistrome modulating LAMC1 and Mcl-1 in prostate cancer[J].Mol Endocrinol,2015,29(7):1037-1054.
    [12]
    Liu C,Duan P,Li B,et al.miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1[J].Oncol Lett,2015,9(1):96-102.
    [13]
    Tang W,Zhu Y,Gao J,et al.MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4[J].Br J Cancer,2014,110(2):450-458.
    [14]
    Shih HH,Xiu M,Berasi SP,et al.HMG box transcriptional repressor HBP1 maintains a proliferation barrier in differentiated liver tissue[J].Mol Cell Biol,2001,21(17):5723-5732.
    [15]
    Huang JS, Xiao R, Pang Y, et al. HBP1—an important tumor inhibitor[J].Chin J Biochem Mol Biol(中国生物化学与分子生物学报),2012,28(10):913-918.
    [16]
    Paulson KE,Rieger-Christ K,McDevitt MA,et al.Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer[J].Cancer Res,2007,67(13):6136-6145.
    [17]
    Yee AS,Paulson EK,McDevitt MA,et al.The HBP1 transcriptional repressor and the p38 MAP kinase:unlikely partners in G1 regulation and tumor suppression[J].Gene,2004,336(1):1-13.
    [18]
    Sampson EM,Haque ZK,Ku MC,et al.Negative regulation of the Wnt/b-catenin pathway by the transcriptional repressor HBP1[J].EMBO J,2001,20(16):4500-4511.
    [19]
    Qin X,Zhang H,Zhou X,et al.Proliferation and migration mediated by Dkk-1/Wnt/b-catenin cascade in a model of hepatocellular carcinoma cells[J].Transl Res,2007,150(5):281-294.
    [20]
    Wang Z,Ma Q.Beta-catenin is a promising key factor in the SDF-1/CXCR4 axis on metastasis of pancreatic cancer[J].Med Hypotheses,2007,69(4):816-820.
    • Related Articles

  • Related Articles

    [1]ZHANG Wanyue, LIU Wei, XU Hang, GAO Xiangdong. Advanced structure analysis and structure-activity relationship of polysaccharide SGP-2 from Sarcandra glabra[J]. Journal of China Pharmaceutical University, 2021, 52(5): 630-635. DOI: 10.11665/j.issn.1000-5048.20210517
    [2]CHEN Shumin, HUANG Wenlong, HU Guoqiang. Synthesis and antitumor activity of fluoroquinolone C-3 isostere V: ciprofloxacin acylhydrazone derivatives[J]. Journal of China Pharmaceutical University, 2014, 45(2): 161-164. DOI: 10.11665/j.issn.1000-5048.20140205
    [3]LIU Haomiao, HU Xiaowen, ZHOU Jinpei, ZHANG Huibin. Advances of G protein coupled receptor 119 agonists and their structure-activity relationship[J]. Journal of China Pharmaceutical University, 2013, 44(1): 11-19. DOI: 10.11665/j.issn.1000-5048.20130102
    [4]2D-QSAR and HQSAR study on quantitative structure-activity relationship of 6-O-aryl ketolides derivatives[J]. Journal of China Pharmaceutical University, 2010, 41(3): 208-215.
    [5]ZHENG Kai-bo, SUN Cheng-bin, MAO Hai-li, YANG Zai-bo. Progress in the research of chemical structural modification of ursolic acid and structure-activity relationship[J]. Journal of China Pharmaceutical University, 2009, 40(6): 580-584.
    [6]Studies on the Quantitative Structure activity Relationship of the Quinolone Antibacterials Against Mycobacteria:Effect of Structural Changes at C 7[J]. Journal of China Pharmaceutical University, 1999, (1): 18-20.
    [7]Synthesis and Anesthetic Activity of 3-Methyl Fentanyl Derivatives[J]. Journal of China Pharmaceutical University, 1993, (5): 257-263.
    [8]Synthesis, Analgesic Activity and Structure-Activity Relationship of 4-N-Cyclohexyl Analogs of Some Fentanyl Derivatives[J]. Journal of China Pharmaceutical University, 1993, (3): 139-144.
    [9]Structural-Activity Relations Study on the Derivatives of 3,4-Dimethoxyphenylenediamine[J]. Journal of China Pharmaceutical University, 1992, (4): 217-220.
    [10]DETERMINATION OF HYDROLYSIS RATE AND PRELIMINARY STRUCTURE-ACTIVITY RELATIONSHIP OF THIOHYDANTOIN DERIVATIVES[J]. Journal of China Pharmaceutical University, 1989, (4): 199-202.

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292707

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return